Table: Solasia Pharma -9-MTH group results (IFRS)

Solasia Pharma KK

10/11/2021 06:45

Nov 10 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended        Year to  
                  Sep 30, 2021        Sep 30, 2020      Dec 31, 2021  
                     LATEST             YEAR-AGO           COMPANY    
                     RESULTS             RESULT           FORECAST    
  Sales              283 mln             287 mln           600 mln    
                   (-1.5 pct)          (-1.3 pct)        (+32.1 pct)  
  Operating         loss 2.06           loss 1.90         loss 2.50   
  Pretax            loss 2.08           loss 1.93         loss 2.50   
  Net               loss 2.11           loss 1.94         loss 2.50   
  EPS Basic      loss 16.36 yen      loss 16.64 yen    loss 18.73 yen 
  EPS Diluted    loss 16.36 yen      loss 16.64 yen                   
  Ann Div                                  NIL               NIL      
  -Q2 Div              NIL                 NIL                        
  -Q4 Div                                  NIL               NIL      
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T